July 16, 2026 |
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.

Simon Davenport, Global Head of Environments at Inizio Engage, explores the characteristics that set the most successful congress experiences apart. Drawing on observations from the exhibition floor, the article highlights three key principles: creating a clear and consistent scientific narrative, designing interactions that genuinely enhance engagement rather than relying on technology for its own sake, and building flexible experiences that allow HCPs to engage at different levels. The article explains why thoughtful experience design is becoming increasingly important as congress environments grow more competitive.
Read full article here.
Nick Bellomo, VP of Experience and Technology at Inizio Medical, examines the technology and engagement innovations that stood out across ASCO® 2026. From immersive LED environments and AI-powered interactions to tactile, low-tech activations, the article explores how organisations are rethinking the use of technology to create more meaningful scientific engagement. It concludes that the most effective congress experiences combine creativity with purposeful design to strengthen scientific communication and generate valuable behavioural insights.
Read full article here.
Lynsey Holbrook, Global Client Development Director at Inizio Engage, focuses on the growing complexity of congress planning and the challenge of demonstrating return on investment. The article explores why many pharmaceutical organisations struggle to connect strategy, execution and measurement, despite increasing investment in congresses. It outlines how a more connected approach can help teams align stakeholders, create more coordinated delegate experiences and measure the activities that drive meaningful scientific and commercial outcomes.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.
In this webcast, Senior Director, Richard Head and Director of The Medical Futurist, Dr. Bertalan Mesko host a live virtual Q&A discussion about the future of digital health.
Research Partnership ranks 12th in fastest growing UK market research agency league tables
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape…
Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.
*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded…
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.
Senior Analytics Specialist joins Research Partnership
Dynamic data-driven solution unlocks deeper insights and powers stronger omnichannel experiences.
All change – how untangling human behaviour can encourage better health
